We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

CTI BioPharma Settles Investor Testing Info Row For $20M

Law360, New York (September 5, 2017, 5:25 PM EDT) -- CTI BioPharma Corp. and its executives will pay $20 million to a proposed class of investors for allegedly withholding information about patient deaths during clinical trials for a myelofibrosis drug, which led to a stock drop when the U.S. Food and Drug Administration stopped the trials, the investors told a Washington federal court on Friday.

The proposed class, led by DAFNA LifeScience LP, said in a motion for preliminary approval of the settlement and class certification that CTI has agreed to pay following talks with JAMS...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

McGlothin v. CTI BioPharma Corp et al


Case Number

2:16-cv-00216

Court

Washington Western

Nature of Suit

Securities/Commodities

Judge

Robert S. Lasnik

Date Filed

February 12, 2016

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.